Subject: Real World Survey to understand the usage pattern of Antiulcer drugs in the management of GERD during pregnancy.
Despite low disease-related mortality, GERD manifests in poor health-related quality of life, which results in lower physical and mental health, affecting the quality of sleeping, eating, and drinking. Thus, appropriate management strategies are required for immediate control of symptoms and to prevent further deterioration in the quality of life, and subsequently, the pregnancy’s well-being. Factors that predispose to pathologic reflux include increasing age, lifestyle, certain beverages and food consumption, overweight, obesity, and pregnancy.
Heartburn occurs in approximately 30% to 50% of pregnancies, reaching 80% in some populations. Approximately 17% of pregnant women experience heartburn and regurgitation simultaneously. The incidence of reflux symptoms across the 3 trimesters has recently been reported to be about 25%, with a steady increase in the severity of heartburn over the course of the pregnancy.
The management of GERD during pregnancy focuses on relieving heartburn and regurgitation unless it is associated with alarm symptoms (gastrointestinal blood loss, persistent vomiting, dysphagia, chest pain, and involuntary weight loss). Treatment is aimed at alleviating the symptoms caused by the acid reflux. Some guidelines suggest diet/lifestyle modifications and the use of medications to treat GERD symptoms. These include pharmacological agents such as antacids or alkali mixtures, H2 receptor antagonists (H2RA), or proton pump inhibitors (PPI).
This survey is designed to understand the perception of healthcare professionals towards the use of antiulcer drugs during pregnancy.
If you agree to participate, you must respond to the survey questionnaire.
We hope you will consent to participate in this survey. If you do, please sign and return the enclosed reply along with your visiting card for the accuracy of records.
|
}}){kind=logo}